Adding Exact Sciences to My Watchlist: Breaking Down the Q4 2025 Earnings

When you’re building your investment portfolio, finding the right diagnostic companies to monitor is crucial. Exact Sciences Corporation recently released its full-year and fourth-quarter 2025 earnings, and the results offer meaningful insights for those considering whether to add this stock to their watchlist. Here’s what investors need to know about EXAS’s latest financial performance and what it signals for the future.

The Numbers: Q4 Revenue Beat & Earnings Alignment

Exact Sciences posted a fourth-quarter net loss of 21 cents per share, which was slightly worse than the 6-cent loss from Q4 2024, yet this figure aligned precisely with analyst expectations. For the full year 2025, the company swung to profitability with earnings of 7 cents per share, a notable turnaround from the 23-cent loss in 2024.

The real standout was on the revenue side. Consolidated revenues for Q4 reached $878.4 million, representing a 23.1% increase year-over-year on a reported basis and 23% on a core basis. This beat the Zacks Consensus Estimate by 2.1%, signaling that the company’s core business continues to perform ahead of expectations. Full-year 2025 revenues totaled $3.25 billion, up 17.7% reported and 18% on a core basis. Following the earnings announcement, EXAS shares moved modestly higher, gaining 0.07% in market trading.

For someone building a my watchlist of healthcare stocks, these revenue results deserve attention. The consistent beat suggests operational momentum that extends beyond what the Street anticipated.

Business Segments Drive Growth: Screening and Precision Oncology Momentum

Understanding where revenue actually comes from matters when evaluating stocks for your watchlist. Exact Sciences operates through two primary revenue drivers.

The Screening segment, which includes Cologuard testing and PreventionGenetics services, generated $695.1 million in Q4 revenues, reflecting a robust 26% year-over-year increase. This segment remains the company’s largest contributor and demonstrates sustained demand for its colorectal and genetic screening offerings.

The Precision Oncology segment, encompassing Oncotype diagnostics and related therapy selection products, contributed $183.2 million, up 14% year-over-year and 12% on a core basis. While smaller than Screening, this segment’s growth trajectory highlights Exact Sciences’ expanding footprint in cancer diagnostics—a high-value market segment increasingly important to healthcare providers and pharma companies alike.

Margin Expansion & Rising Costs: The Mixed Picture

The margin dynamics reveal both encouragement and caution. Gross profit climbed 25% year-over-year to $615.8 million, with gross margin expanding by 106 basis points to 70.1%. This improvement reflects the company’s ability to scale operations more efficiently—a positive indicator that operational leverage is beginning to work in its favor.

However, the expense side tells a more complex story. Research and development spending nearly doubled, jumping 96% to $191.5 million, while sales and marketing expenses rose 18% to $288.5 million. General and administrative costs increased 14.1% to $218 million. Adjusted operating expenses reached $698 million, up 30.9% year-over-year, resulting in an adjusted operating loss of $82.2 million compared with a $40.8 million loss in the prior year.

This divergence between margin expansion and rising losses is important for my watchlist investors to understand: the company is scaling aggressively to capture market share, but that strategy is currently more expensive than current revenues can support.

Cash Position Strong, But Abbott Merger Timeline Matters

Exact Sciences ended Q4 2025 with $964.7 million in cash and marketable securities, down from $1.04 billion at year-end 2024. While the absolute level remains solid, the decline reflects continued cash burn from operations and investments.

On the positive side, cumulative net cash provided by operating activities totaled $491.4 million, more than double the $210.5 million generated in the prior year. This improvement in cash generation from core operations is encouraging and suggests the company is moving toward cash flow positivity.

A transformational development looming over these results is Exact Sciences’ announced merger with Abbott Laboratories. The companies entered into a merger agreement in November 2025, and both parties are actively working with regulators toward a targeted close in Q2 2026. This transaction will fundamentally alter EXAS’s trajectory and should weigh into any my watchlist decision.

Key Developments and Forward Outlook

Beyond the headline numbers, several clinical advances warrant attention. Exact Sciences announced favorable first clinical study results from its Oncodetect molecular residual disease test in breast cancer—a potentially significant advancement in post-treatment monitoring. The company also released pivotal validation results from the ALTUS study, supporting its precision oncology pipeline expansion.

These clinical wins, combined with revenue outperformance, suggest the underlying business remains competitive and innovative. The challenge is whether the company can achieve profitability before the Abbott transaction closes, or whether the merger represents a transition point where the combined entity will drive value creation differently.

Should You Add EXAS to Your Watchlist?

Exact Sciences presents a nuanced investment case. On the positive side, you’ve got revenue growth that consistently beats expectations, meaningful margin expansion potential, and an expanding addressable market in diagnostics. The company’s dual revenue streams in Screening and Precision Oncology provide diversification within healthcare.

On the cautionary side, rising operating losses, accelerating research spending, and the looming structural change from the Abbott merger create uncertainty. The company’s current trajectory suggests losses may persist in the near term, though the cash flow inflection offers some optimism.

For investors building a diversified my watchlist in healthcare, Exact Sciences merits inclusion—but with the understanding that you’re betting on either near-term profitability improvements or long-term value creation within Abbott’s broader platform. The Q4 results demonstrate operational strength, but the path to sustained profitability remains the key question investors should monitor closely in coming quarters.